If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Omvoh ® (mirikizumab-mrkz) injection
300 mg/15 mL, 100 mg/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Should the dose of Omvoh® (mirikizumab-mrkz) be adjusted for hepatic function?
No dosing adjustments are needed in patients with hepatic impairment.
Pharmacokinetics of Mirikizumab in Hepatic Impairment
Mirikizumab is a humanized immunoglobulin G4 (IgG4) monoclonal antibody and is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.1
Specific clinical pharmacology studies to evaluate the effects of hepatic impairment on the pharmacokinetics of mirikizumab have not been conducted.2
Population pharmacokinetic analysis showed that mirikizumab pharmacokinetics were not affected by total bilirubin in the range of
- 1.5 to 29 µmol/L in patients with ulcerative colitis, and
- 1.5 to 36 μmol/L in patients with Crohn's disease.2
Enclosed Prescribing Information
References
1Omvoh [package insert]. Indianapolis, IN: Eli Lilly and Company; 2025.
2Data on file, Eli Lilly and Company and/or one of its subsidiaries.
Date of Last Review: January 15, 2025